|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01873 VIVA BIOTECH
Nominal 
1.335 -0.030 (-2.198%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 1,006,519 | 20.994% | 1,729,446 | 1,986,651 | 2,155,578 | 2,379,631 |
| Cost of Sales | (664,789) | 34.997% | (1,073,885) | (1,299,252) | (1,417,146) | (1,563,952) |
| Gross Profit | 341,730 | 0.678% | 655,561 | 687,399 | 738,432 | 815,679 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 30,237 | -42.946% | 152,601 | 78,106 | 154,515 | (363,539) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (297) | -28.947% | (4,497) | (95) | 0 | 0 | |
| Profit / (Loss) before Taxation | 109,598 | -36.167% | 318,002 | 295,705 | (55,953) | (459,165) | |
| Taxation | (8,719) | -62.187% | (48,735) | (73,718) | (43,837) | (45,055) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (20,802) | -22.473% | (49,506) | (54,693) | (16,323) | (24,255) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 80,077 | -34.258% | 219,761 | 167,294 | (116,113) | (528,475) | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 6,155 | -32.251% | 20,598 | 33,353 | 149,207 | 163,068 |
| Depreciation & Amortisation | 100,417 | -6.819% | 211,049 | 213,861 | 208,389 | 178,301 |
| Directors' Emoluments | -- | -- | 9,159 | 8,577 | 9,655 | 10,420 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified (Modified Report) |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 4.000 | -33.333% | 10.000 | 8.000 | -6.000 | -28.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.110 | 0.175 | 0.198 | 0.202 |
| NBV per share ($) | 1.883 | -- | 1.876 | 1.783 | 1.706 | 1.643 |
| Remarks: | Real time quote last updated: 04/09/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 80,077 |
| %Change | -34.258% |
| EPS / (LPS) | RMB 0.040 |
| NBV Per Share (¥) | RMB 1.883 |